The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents

Women and Health

Volumn 31, Issue 1, 2000, Pages 71-85

  Breuer, Brenda ^a   Anderson, Richard ^b  

^a Jewish Home and Hospital   (United States)

^b SAS INSTITUTE INC   (United States)

Author keywords

Adl; Dementia; Depression; Nursing home; Tamoxifen

Indexed keywords

ESTROGEN; RALOXIFENE; TAMOXIFEN;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BED; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DATA ANALYSIS; DECISION MAKING; DEMENTIA; DEPENDENT PERSONALITY DISORDER; DEPRESSION; EATING; ETHNOLOGY; FEMALE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INDEPENDENCE; LOCOMOTION; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL RECORD; NURSING HOME; PERSONAL HYGIENE; PREVALENCE; STATISTICS; UNITED STATES;

EID: 0033782183     PISSN: 03630242     EISSN: 15410331     Source Type: Journal    
DOI: 10.1300/J013v31n01_05     Document Type: Article

References (45)

1. Early Breast Cancer Trialists' Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy:133 randomized trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women; Part I. The Lancet, 339:1–15.
2. Early Breast Cancer Trialists' Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy:133 randomized trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women; Part II. The Lancet, 339:71–85.
3. Fisher, B, Costantino, J, Redmond, C, Poisson, R, Bowman, D, Couture, J. 1989. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New England Journal of Medicine, 320:479–484.
4. Oxman, TE, and Hull, JG. 1997. Social support, depression, and activities of daily living in older heart surgery patients. J Gerontol B Psychol Sci Soc Sci
5. Schneider, DP, Fries, BE, Foley, WJ, Desmond, M, and Gormley, WJ. 1988. Case mix for nursing home payment:Resource utilization groups, version II. Health Care Financing Review,:39–52.
6. Landis, JR, and Koch, GG. 1977. The measurement of observer agreement for categorical data. Biometrics, 33:159–174.
7. Hawes, C, Morris, JN, Phillips, CD, Mor, V, Fries, BE, and Nonemaker, S., 1995. Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening MDS. The Gerontologist, 35:172–178.
8. Casten, R, Lawton, MP, Parmelee, PA, and Kleban, MH. 1998. Psychometric characteristics of the Minimum Data Set I:Confirmatory factor analysis. J Am Geriatr Soc, 46:726–735.
9. Breuer, B, Wallenstein, S, and Anderson, R., 1998. Effect of tamoxifen on bone fractures in elderly nursing home residents. J Am Geriatr Soc, 46:968–972.
10. Health Care Financing Administration. 1995. Minimum data set version 2 user's manual, 1st ed., Needham Heights, MA:Eliot press.
11. SAS Institute Inc. 1990. SAS procedures guide, version 6 third edition, Cary, N.C.:SAS.
12. SAS Institute Inc. 1989. SAS/STAT user's guide, version 6, fourth edition, Cary, N.C.:SAS.
13. Siegel, S, and Castellan, NJ, Jr. 1988. Nonparametric statistics for the behavioral sciences, 2 ed., New York:McGraw-Hill Book Company.
14. Sherwin, BB. 1996. Hormones, mood, and cognitive functioning in postmenopausal women. Obstet Gynecol, 87(2 Suppl):20S–26S.
15. Fillit, H., 1995. Future therapeutic developments of estrogen use. J Clin Pharmacol, 35(9 Suppl):25S–28S.
16. Love, RR, Cameron, L, Connell, BL, and Leventhal, H., 1991. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med, 151:1842–1847.
17. Cathcart, CK, Jones, SE, Pumroy, CS, Peters, GN, Knox, SM, and Cheek, JH. 1993. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat, 27(3):277–281.
18. Henderson, VW, Paganini-Hill, A, Emanuel, CK, Dunn, ME, and Buckwalter, JG. 1994. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol, 51:896–900.
19. Honjo, H, Ogino, Y, Naitoh, K, Urabe, M, Kitawaki, J, Yasuda, J. 1989. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem, 34(1-6):521–525.
20. Brenner, DE, Kukull, WA, Stergachis, A, van Belle, G, Bowen, JD, McCormick, WC. 1994. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease:A population-based case-control study. Am J Epidemiol, 140(3):262–267.
21. Barrett-Connor, E, and Kritz-Silverstein, D., 1993. Estrogen replacement therapy and cognitive function in older women. JAMA, 269(20):2637–2641.
22. Birge, SJ. 1996. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia?. J Am Geriatr Soc, 44:865–870.
23. Yaffe, K, Sawaya, G, Lieberburg, I, and Grady, D., 1998. Estrogen therapy in postmenopausal women:Effects on cognitive function and dementia. JAMA, 279(9):688–695.
24. Rodriguez, MM, and Grossberg, GT. 1998. Estrogen as a psychotherapeutic agent. Clin Geriatr Med, 14(1):177–189.
25. Hutchins, LF, Unger, JM, Crowley, JJ, Coltman, CA, Jr. and Albain, KS. 1999. Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. N Engl J Med, 341(27):2061–2067.
26. Lawton, MP, Casten, R, Parmelee, PA, Van Haitsma, K, Corn, J, and Kleban, MH. 1998. Psychometric characteristics of the minimum data set, II:Validity. J Am Geriatr Soc, 46:736–744.
27. Morris, JN, Hawes, C, Fries, BE, Phillips, CD, Mor, V, Katz, S. 1990. Designing the national resident assessment instrument for nursing homes. The Gerontologist, 30:293–307.
28. Frederiksen, K, Tariot, P, and De Jonghe, E., 1996. Minimum data set plus (MDS +) scores compared with scores from five rating scales. J Am Geriatr Soc, 44:305–309.
29. Dosemeci, M, Wacholder, S, and Lubin, JH. 1990. Does nondifferential misclassification of exposure always bias a true effect toward the null value?. Am J Epidemiol, 132:746–748.
30. Lien, EA, Solheim, E, and Ueland, PM. 1991. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res, 51:4837–4844.
31. Lien, EA, Wester, K, Lonning, PE, Solheim, E, and Ueland, PM. 1991. Distribution of ta-moxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer, 63:641–645.
32. Powles, TJ, Jones, AL, Ashley, SE, O'Brien, ME, Tidy, VA, Treleavan, J. 1994. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat, 31(1):73–82.
33. Zeleniuch-Jacquotte, A, Toniolo, P, Levitz, M, Shore, RE, Koenig, KL, Banerjee, S. 1995. Endogenous estrogens and risk of breast cancer by estrogen receptor status:A prospective study in postmenopausal women. Cancer Epidemiol. Biomarkers Prev, 4:857–860.
34. Barrett-Connor, E., 1994. Postmenopausal estrogen and the risk of breast cancer. Ann Epidemiology, 4:177–180.
35. Mayeux, R, Schupf, N, and Apolipoprotein, E. 1995. and Alzheimer's disease:The implications of progress in molecular medicine. Am J Public Health, 85(9):1280–1284.
36. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, and Stadlan, EM. 1984. Clinical diagnosis of Alzheimer's disease:Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34:939–944.
37. Snowdon, DA, Greiner, LH, Mortimer, JA, Riley, KP, Greiner, PA, and Markesbery, WR. 1997. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA, 277:813–817.
38. Stoudemire, A, Hill, C, Gulley, LR, and Morris, R., 1989. Neuropsychological and biomedical assessment of depression-dementia syndromes. J Neuropsychiatry and Clin Neurosci, 1:347–361.
39. Scott, JA, Da Camara, CC, and Early, JE. 1999. Raloxifene:A selective estrogen receptor modulator. Am Fam Physician, 60(4):1131–1139.
40. Agnusdei, D., 1999. Clinical efficacy of raloxifene in postmenopausal women. Eur J Obstet Gynecol Reprod Biol, 85(1):43–46.
41. Balfour, JA, and Goa, KL. 1998. Raloxifene. Drugs Aging, 12(4):335–341.
42. Ensrud, K, Black, D, Recker, R, Harris, S, Delmas, P, Pols, H. 1998. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research
43. Birge, SJ. 1999. Can falls and hip fracture be prevented in frail older adults?. J Am Geriatr Soc, 47(10):1265–1266.
44. Fisher, B, Costantino, JP, Wickerham, DL, Redmond, CK, Kavanah, M, Cronin, WM. 1998. Tamoxifen for prevention of breast cancer:Report of The National Surgical Adjuvant Breast And Bowel Project P-1 Study. J Natl Cancer Inst, 90(18):1371–1388.
45. Cummings, SR, Eckert, S, Krueger, KA, Grady, D, Powles, TJ, Cauley, JA. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA, 281:2189–2197.